|
California Institute for Biomedical Research |
Kristen Johnson |
Clinical Trial Stage Projects |
Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
|
California Institute for Biomedical Research |
Peter Schultz |
Late Stage Preclinical Projects |
Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$1,667,832 |
|
California Institute for Biomedical Research |
Peter Schultz |
Preclinical Development Awards |
Development of a Chondrogenic Drug Candidate Targeting Cartilage-residing Mesenchymal Stem Cells for the Treatment of Osteoarthritis |
$2,306,703 |
